A method establishment and comparison of in vivo lung cancer model development 
platforms for evaluation of tumour metabolism and pharmaceutical efficacy

Liang, T.-L.; Li, R.-Z.; Mai, C.-T.; Guan, X.-X.; Li, J.-X.; Wang, X.-R.; Ma, L.-R.; Zhang, F.-Y.; Wang, J.; He, F.; Pan, H.-D.; Zhou, H.; Yan, P.-Y.; Fan, X.-X.; Wu, Q.-B.; Neher, Erwin; Liu, L.; Xie, Y.; Leung, E.L.-H.; Yao, X.-J.

doi:10.1016/j.phymed.2021.153831

Item

ITEM ACTIONSEXPORT

Add to Basket

Local TagsRelease HistoryDetailsSummary

Released

Journal Article

A method establishment and comparison of in vivo lung cancer model development platforms for evaluation of tumour metabolism and pharmaceutical efficacy

MPS-Authors

Liang, T.-L.
Emeritus Group of Membrane Biophysics, Max Planck Institute for Multidisciplinary Sciences, Max Planck Society;

/persons/resource/persons15570

Neher, Erwin
Emeritus Group of Membrane Biophysics, Max Planck Institute for Multidisciplinary Sciences, Max Planck Society;

External Resource

No external resources are shared

Fulltext (restricted access)

There are currently no full texts shared for your IP range.

Fulltext (public)

There are no public fulltexts stored in PuRe

Supplementary Material (public)

There is no public supplementary material available

Citation

Liang, T.-L., Li, R.-Z., Mai, C.-T., Guan, X.-X., Li, J.-X., Wang, X.-R., et al. (2022). A method establishment and comparison of in vivo lung cancer model development platforms for evaluation of tumour metabolism and pharmaceutical efficacy. Phytomedicine, 96: 153831. doi:10.1016/j.phymed.2021.153831.

Cite as: https://hdl.handle.net/21.11116/0000-000C-0EE1-7

Abstract

Background:
Currently, the identification of accurate biomarkers for the diagnosis of patients with early-stage lung cancer remains difficult. Fortunately, metabolomics technology can be used to improve the detection of plasma metabolic biomarkers for lung cancer. In a previous study, we successfully utilised machine learning methods to identify significant metabolic markers for early-stage lung cancer diagnosis. However, a related research platform for the investigation of tumour metabolism and drug efficacy is still lacking.

Hypothesis/Purpose:
A novel methodology for the comprehensive evaluation of the internal tumour–metabolic profile and drug evaluation needs to be established.

Methods:
The optimal location for tumour cell inoculation was identified in mouse chest for the non-traumatic orthotopic lung cancer mouse model. Microcomputed tomography (micro-CT) was applied to monitor lung tumour growth. Proscillaridin A (P.A) and cisplatin (CDDP) were utilised to verify the anti-lung cancer efficacy of the platform. The top five clinically valid biomarkers, including proline, L-kynurenine, spermidine, taurine and palmitoyl-L-carnitine, were selected as the evaluation indices to obtain a suitable lung cancer mouse model for clinical metabolomics research by ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS).

Results:
The platform was successfully established, achieving 100% tumour development rate and 0% surgery mortality. P.A and CDDP had significant anti-lung cancer efficacy in the platform. Compared with the control group, four biomarkers in the orthotopic model and two biomarkers in the metastatic model had significantly higher abundance. Principal component analysis (PCA) showed a significant separation between the orthotopic/metastatic model and the control/subcutaneous/KRAS transgenic model. The platform was mainly involved in arginine and proline metabolism, tryptophan metabolism, and taurine and hypotaurine metabolism.

Conclusion:
This study is the first to simulate clinical metabolomics by comparing the metabolic phenotype of plasma in different lung cancer mouse models. We found that the orthotopic model was the most suitable for tumour metabolism. Furthermore, the anti-tumour drug efficacy was verified in the platform. The platform can very well match the clinical reality, providing better lung cancer diagnosis and securing more precise evidence for drug evaluation in the future.